glucagon in retatrutide Calling a “GLP-3” is usually a quick sign that you don't understand the underlying biology. Retatrutide is a NuSH-based triple agonist—it targets GLP-1, GIP, and receptors. Only one of those retatrutide triple agonist glp-1 gip

Each of the experiments is in a preclinical laboratory phase, and the peptide is currently used to do scientific research only

One phase 3 clinical trial found that survodutide led to an average 12% to 18.7% body weight reduction , depending on dose, in adults with obesity and without diabetes after 76 weeks compared to 5% in the placebo group

It is just unlikely to be the difference-maker that marketing materials suggest

C.BckM.et al (2021)

Those in the higher arms were begun at a lower amount and stepped up at four-week intervals until they reached their assigned arm, and the protocol deliberately tested two different starting amounts within the 4 mg and 8 mg arms to compare how escalation pace affected tolerability